When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the ...

Company is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation ...

Qure’s AMT-130 faces FDA efficacy doubts after 12-month data. QURE's upside now hinges on political pressure. Read here for ...

As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...

This transition is explored in “Embodied Artificial Intelligence in Healthcare: A Systematic Review of Robotic Perception, ...

"Disappointing" trial results, but some researchers remain hopeful ...

News headlines often compress complex science into a simple storyline: If two things are happening at the same time, one must ...

Socioemotional skills programs are widely used to promote economic empowerment, yet their returns may vary by skill-type and gender. This paper evaluates a socioemotional skills intervention for 4,500 ...

Divergence in the post-progression interval suggests disparities may concentrate in subsequent-line therapy, surveillance, supportive care, or access to timely interventions outside trial ...

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...

“Designing treatments unique to individual patients has always been the promised goal of personalized medicine. After 25 years the FDA has, for the first time, outlined a framework to facilitate these ...

Internal Family Systems has become a wildly popular form of therapy over the past few years. Some of my friends swear by it.